Frontline Plc logo

Frontline Plc (FRO)

Market Closed
9 Dec, 18:40
NYSE NYSE
$
22. 80
-0.71
-3.04%
$
5.24B Market Cap
5.71 P/E Ratio
2.48% Div Yield
1,379,106 Volume
2.69 Eps
$ 23.51
Previous Close
Day Range
22.74 23.28
Year Range
12.4 26
Want to track FRO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 79 days
Frontline: Large Fleet, Excellent Specs, And Attractive Yields

Frontline: Large Fleet, Excellent Specs, And Attractive Yields

I maintain a Buy rating for Frontline due to its large, modern fleet, strong balance sheet, and attractive dividend yield. FRO's fleet consists of 82 tankers with an average age of 6.2 years. 56% of the ships are equipped with scrubbers. Despite high leverage, FRO's operating figures and cash reserves adequately cover debt service costs, ensuring financial stability.

Seekingalpha | 1 year ago
Frontline plc (FRO) Q2 2024 Earnings Call Transcript

Frontline plc (FRO) Q2 2024 Earnings Call Transcript

Frontline plc (NYSE:FRO ) Q2 2024 Earnings Conference Call August 30, 2024 9:00 AM ET Company Participants Lars Barstad - CEO Inger Klemp - CFO Conference Call Participants Jonathan Chappell - Evercore ISI Omar Nokta - Jefferies Operator Good day and thank you for standing by. Welcome to the Second Quarter 2024 Frontline plc Earnings Conference Call.

Seekingalpha | 1 year ago
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks* Outcomes also expected to identify recommended Phase 2 dose APVO436 renamed as mipletamig: Aptevo adopts new generic name for future use SEATTLE, WA / ACCESSWIRE / August 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today, announced initiation of the Company's Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate APVO436 in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts.

Accesswire | 1 year ago
Frontline Plc's Stock And Fleet Are On The Upswing

Frontline Plc's Stock And Fleet Are On The Upswing

Frontline plc stock is rated as a buy-to-strong buy opportunity after a recent drop in share price. Growth opportunities in the marine shipping industry outweigh risks, with demand for crude tankers expected to remain high in the coming years. Frontline plc has a high dividend yield of 10.9% and strong financial metrics, despite accumulating debt to finance its fleet of tankers.

Seekingalpha | 1 year ago
Buy alert: 2 high-yield dividend stocks with ‘Strong Buy' rating for July 2024

Buy alert: 2 high-yield dividend stocks with ‘Strong Buy' rating for July 2024

The Fed's anticipated rate cut could make high-yield stocks more attractive compared to bonds. When interest rates fall, existing bonds become less appealing, potentially leading investors towards higher-yielding equities.

Finbold | 1 year ago
Hot Stocks: 3 Untapped Opportunities for a 1,000% Return

Hot Stocks: 3 Untapped Opportunities for a 1,000% Return

Finding high-return stock opportunities in the market may transform investors' lives. Here, the exploration focuses on three unexplored stock possibilities that might yield remarkable returns of up to 1,000%.

Investorplace | 1 year ago
Frontline's Aggressive Acquisition Strategy Pays Off Amid Global Disruptions

Frontline's Aggressive Acquisition Strategy Pays Off Amid Global Disruptions

Frontline reported strong earnings and distributions, indicating a positive outlook for the company. The company's fleet consists of VLCCs, Suezmaxes, and LR2 tankers, with a focus on fuel efficiency and scrubber-fitted vessels. The war in Ukraine and disruptions in the Suez Canal are expected to continue to impact rates.

Seekingalpha | 1 year ago
Frontline plc (FRO) Q1 2024 Earnings Call Transcript

Frontline plc (FRO) Q1 2024 Earnings Call Transcript

Frontline plc (NYSE:FRO ) Q1 2024 Earnings Conference Call May 30, 2024 9:00 AM ET Company Participants Lars Barstad - Chief Executive Officer Inger Klemp - Chief Financial Officer Conference Call Participants Omar Nokta - Jefferies Gregory Lewis - BTIG Petter Haugen - ABG Sundal Collier Lars Barstad Dear, all. Thank you for dialing in to Frontline's First Quarter Earnings Call.

Seekingalpha | 1 year ago
Is a Beat in Store for Frontline (FRO) in Q1 Earnings?

Is a Beat in Store for Frontline (FRO) in Q1 Earnings?

Frontline's (FRO) Q1 performance is expected to be affected by supply-chain disruptions.

Zacks | 1 year ago
Although Frontline Is Up 83% In 1 Year, We Think There Is More To Come

Although Frontline Is Up 83% In 1 Year, We Think There Is More To Come

We examine earnings potential from the acquisition of 24 modern VLCCs from Euronav. The gearing ratio is expected to increase from 62% to 65% in Q1 2024. Favorable supply and demand dynamics over the next two to three years support higher earnings for VLCC.

Seekingalpha | 1 year ago